The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of pulmonary fibrosis, including usual interstitial pneumonia and idiopathic pulmonary fibrosis, and pharmaceutical compositions comprising such alpha helix mimetic β-catenin inhibitors.
